Bristol-Myers Squibb Co (BMY)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$52.41

Buy

$52.50

arrow-up$1.21 (+2.36%)

Prices updated at 13 Dec 2025, 00:52 EST

Prices minimum 15 mins delay

Prices in USD

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

S&P 500

-1.07%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2023	2024
	45,006m	48,300m
	34,313m	34,332m
	8,195m	5,887m
	18.21	12.19
	8,025m	-8,948m
	19,366m	3,168m
Sales, General and administrative	7,772m	8,414m
Interest expenses	1,166m	1,947m
Provision for income taxes	400m	554m
Operating expenses	26,118m	28,445m
Income before taxes	8,440m	-8,379m
Net income available to common shareholders	8,025m	-8,948m
	3.88	-4.41
Net interest income	-1,166m	-1,947m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	3.86	-4.41
Free cash flow per share	5.5655	6.8071
Book value/share	14.3483	8.4485
Debt equity ratio	1.297418	2.998041

Balance sheet

Year chevron-l-regular chevron-r-regular	2023	2024
Current assets	31,770m	29,780m
Current liabilities	22,262m	23,774m
Total capital	66,083m	63,938m
Total debt	41,464m	51,200m
Total equity	29,430m	16,335m
Total non current liabilities	-	-
Loans	36,653m	47,603m
Total assets	95,159m	92,603m
Total liabilities	-	-
Cash and cash equivalents	11,464m	10,346m
Common stock	2,021m	2,029m

Cash flow

Year chevron-l-regular chevron-r-regular	2023	2024
Cash at beginning of period	9,325m	11,519m
Cash dividends paid	-4,744m	-4,863m
	12,651m	13,942m
Investments (gains) losses	-2,295m	-21,352m
	11,519m	10,347m
Net income	-	-
	13,860m	15,190m
	-1,209m	-1,248m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.